Notably, 4.4% (3/68) patients in the PD-1 group and 8.1% (7/86) patients in the PD-L1 group experienced grade 3 pneumonia and needed discontinuation of ICIs. The gene discussed is CD274; the disease is susceptibility to pneumonia measurement.